General Partner Chad Waite of OVP Venture Partners to Chair BIO 2006 Panel on Nanotechnology Applications in Drug Discovery and Development
Waite will be joined by speakers including: James Mahoney, President, CEO & Director of Surface Logix, Inc., Peter Corish, Applications Manager, Oxonica, Plc, Kenneth Bradley, CEO, Arryx, Inc., and Michael Heller, Co-Founder, Nanogen, Inc. and Professor, Department of Bio-Engineering, University of California, San Diego.
“Nanotechnology Applications in Drug Discovery and Development”
The session is sponsored by Johnson & Johnson Corporate Office of Science & Technology (COSAT) and Woodcock Washburn LLP.
About BIO 2006 Chicago Annual International Convention at
McCormick Place Convention Center
The exhibit hall at BIO 2006 will be the largest gathering of biotechnology exhibitors in history, including more than 1,600 companies, organizations and institutions representing every aspect of the biotechnology industry. With 176,000 net square feet of exhibit space, the hall is approximately the size of three football fields.
For more information about BIO 2006, please visit http://www.bio.org/events/2006/. Media registration is complimentary for credentialed members of the news media. Reporters and editors working full-time for print or broadcast news organizations may register onsite with valid media credentials. Freelance journalists and online publications may not register onsite.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
About OVP Venture Partners
Over its 23-year history as an early-stage venture firm, OVP has been funding industry leading start-ups in the Pacific Northwest. In that period, OVP has invested in more than 90 companies and has driven 22 successful IPO's and 28 mergers and acquisitions. The firm has raised six venture funds and currently has $500 million in capital under management.
With a Pacific Northwest-focused strategy and regional presence in Seattle and Portland, OVP seeks opportunities that are at the intersection points between the market's next big waves and those technology strengths native to the region. OVP's focus is on investments in the areas of communications, software, electronics, computational biology, and nanotechnology.
The OVP team includes six venture partners: Chad Waite, Rick LeFaivre and Lucinda Stewart in Seattle; Dave Chen, Gerry Langeler and John Hull in Portland. Partner Chad Waite serves on the Board of the National Venture Capital Association (NVCA) and is Public Outreach Committee Chair.
OVP believes that as part of its regional venture role, it operates not just as an active investor in the best teams and companies, but also as an active member of the regional technology community and a catalyst in creating the region's next growth opportunities. For more information, please go to: www.ovp.com.